The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma
Premal Lulla, Ifigeneia Tzannou, Spyridoula Vasileiou, George Carrum, Carlos A. Ramos, Rammurti T. Kamble, Tao Wang, Meng-Fen Wu, Mrinalini Bilgi, Adrian P. Gee, Shivani Mukhi, Betty Chung, Linghua Wang, Ayumi Watanabe, Manik Kuvalekar, Mira Jeong, Yumei Li, Shamika Ketkar, Matthew French-Kim, Bambi Grilley, Malcolm K. Brenner, Helen E. Heslop, Juan F. Vera, Ann M. Leen
Abstract
) to 21 patients with MM, 9 of whom were at high risk of relapse after a median of 3 lines of prior therapy and 12 with active, relapsed or refractory disease after a median of 3.5 prior lines. The cells were well tolerated, with only two transient, grade III infusion-related adverse events. Furthermore, patients with active relapsed or refractory myeloma enjoyed a longer than expected progression-free survival and responders included three patients who achieved objective responses concomitant with detection of functional TAA-reactive T cell clonotypes derived from the infused mTAA product.